Latest news

November 9, 2022

Debiopharm leads $6M round for YonaLink to Scale Global Growth and Fuel Expansion of Platform Designed to Stream Clinical Trial…

Read more
October 3, 2022

Debiopharm reinforces the bond between Swiss and Japanese cancer research with the 2022 JCA-Mauvernay Award Ceremony

Read more
September 22, 2022

Big Impact, Small Package: Debiopharm Launches a Wazoku Open-Innovation Challenge for Small Antibody Drug Conjugate Technology

Read more
September 13, 2022

Debiopharm Co-leads a 10M USD Series A Round to Accelerate the Development of Genomic Medicines through Artificial Intelligence

Read more
September 7, 2022

One drug for one bug: Debiopharm to discuss the potential of pathogen-specific antibiotics at the 2022 World AMR Congress

Read more
July 25, 2022

Debiopharm’s new agreement with the University of Geneva boosts scientific Innovation Hub in the Lemanic region of Switzerland through the…

Read more
July 11, 2022

Paul Scherrer Institute regains License from Debiopharm for the Development of Tageted Radiopharmaceutical Debio 1124

Read more
July 5, 2022

7e Challenge Qualité de vie du patient : cinq finalistes reçoivent 5000 francs chacun et avancent en finale

Read more
May 9, 2022

Debiopharm leads investment round for evidence-based digital cancer therapeutic app Mika to empower cancer patients

Read more

Stay informed

Don't miss any latest news and announcements on Debiopharm Investment, subscribe to our newsletter.